CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
Beginning June 1, 2020 all 5 CTS laboratories will being transitioning from the Grifols Procleix Ult...
On Wednesday August 15, 2018 at 11:00AM PDT, we will be hosting a webinar regarding the changes to F...
The CTS 2020 Annual Laboratory Survey is on its way to your email box. We would appreciate you takin...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm thi...
As a service to our partners, CTS provides a copy of all licenses and accreditations on our website....
The COVID-19 pandemic has unveiled the huge challenges and risks health workers are facing globally ...